lundi 13 juillet 2020

Tuesday, July 19th 2016 at 11:00am UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system disorders, announced today that Geno Germano has been
appointed to Sage’s Board of Directors.

“The Sage team is excited to welcome Mr. Germano to our Board,” said
Jeff Jonas, M.D., Chief Executive Officer of Sage. “Mr. Germano’s clear
passion for creating medicines that significantly improve patients’
lives is a perfect fit with Sage’s vision and culture. Geno is an
experienced and capable senior executive in the life sciences industry
whose commercial expertise and experience in organizational scaling will
be invaluable to Sage.”

Geno Germano was recently appointed President of Intrexon, a leader in
synthetic biology, effective June 1, 2016. As President, Mr. Germano is
responsible for leading Intrexon’s management team and commercialization
efforts utilizing the Company’s technology platform for
biologically-based solutions across a broad range of industries
including Health, Consumer, Energy, Environment and Food. Mr. Germano
has over 30 years of experience in the pharmaceutical industry and a
consistent track record of improving operating performance and
increasing shareholder value across numerous leadership roles in
multiple therapeutic categories and global markets at Pfizer, Wyeth and
Johnson & Johnson. Prior to joining Intrexon, he was Group President of
Pfizer’s Global Innovative Pharma Business, where he led a growing
global $14 billion business with market-leading medicines and an
extensive portfolio of late-stage development candidates in several
therapeutic areas including cardiovascular, metabolic disease,
neuroscience, inflammation, immunology, and rare diseases. Mr. Germano
was also Co-Chair of the Portfolio Strategy and Investment Committee
focused on maximizing the return on research and development investment
across the Pfizer portfolio. Previously, Mr. Germano served as President
and General Manager of Pfizer’s Specialty Care and Oncology business
units where he led commercial, medical, and post proof-of-concept
pipeline strategy and development across global markets, as well as held
responsibility for driving P&L growth and pipeline value through
disciplined portfolio management. In addition, while in this role he
directed the integration of Wyeth and Pfizer Specialty Care and Vaccines
Businesses and developed top talent within the organization focusing on
the leadership team.

Prior to joining Pfizer, Mr. Germano held numerous executive and
leadership roles at Wyeth Pharmaceuticals including President of Wyeth
U.S., where he was responsible for delivery of operational results
across four business units, as well as President of its Global
Pharmaceutical and Women’s Healthcare Business. He is a member of the
Group of Fifty (G50) and serves on the Board of the Biotechnology
Innovation Organization, as well as on the Advisory Board of the
Healthcare Businesswomen’s Association and as a Trustee of the Albany
College of Pharmacy where he received his Bachelor of Science degree in

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage’s lead program, SAGE-547, is in
Phase 3 clinical development for super-refractory status epilepticus, a
rare and severe seizure disorder, and is being developed for severe PPD.
Sage is developing its next generation modulators, including SAGE-217,
SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders.
For more information, please visit


Investor Contact:
Sage Therapeutics
Paul Cox, 617-299-8377
Suda Communications LLC
Maureen L. Suda, 585-387-9248

Source: Sage Therapeutic

Étiquettes : , , , , , , , ,